COMMUNIQUÉS West-GlobeNewswire

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
27/03/2026
Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27 [...]
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
27/03/2026
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) , a rare primary immunodeficiency Decision based on [...]
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
27/03/2026
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate [...]
IBA delivers strong FY 2025 results with solid execution in all segments
27/03/2026
Read the entire full-year 2025 results press release here Louvain-la-Neuve, Belgium, 27 March 2026 - IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong [...]
UCB - Convening Notice to the General Meeting of the Shareholders 2026
27/03/2026
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “ General Meeting ”) which will be held on Thursday, 30 April 2026 [...]
IBA réalise des résultats solides pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments
27/03/2026
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats annuels 2025 Louvain-La-Neuve, Belgique, 27 mars 2026 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour l' [...]
UCB - Convocation à l'assemblée générale des actionnaires 2026
27/03/2026
CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration invite les actionnaires à l’assemblée générale des actionnaires (« l’Assemblée Générale ») qui se tiendra le jeudi 30 avril 2026 à 11 [...]
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online — 2026 Search Trends and Publicly Available Pricing Information Context
27/03/2026
A 2026 informational overview of publicly available MEDVi tirzepatide GLP-1 pricing details, compounded medication access pathways, program structure, and regulatory context relevant to consumers researching affordable [...]
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
27/03/2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
Gelatine Sculpt Claims Evaluated: Documenting the Gelatin Trick Recipe Investigation for Consumer Safety
27/03/2026
A 2026 consumer transparency report addressing Gelatine Sculpt's "bariatric jelly" terminology, gelatin trick recipe marketing references, GLP-1-related positioning, ingredient disclosure, proprietary blend context, and [...]
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
27/03/2026
Awiqli ® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli ® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these [...]
Radiant Health Centers Names Mark Gonzales Interim CEO Amid Period of Expansion
27/03/2026
Veteran Leader with 15+ Years of Service to Guide Growth, Increase Access to Care, and Deepen Community Impact Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers today announced the appointment of [...]
DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités
26/03/2026
Châtillon, France, 26 mars 2026 DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités Poursuite des avancées du programme de développement clinique du patch VIASKIN® Peanut [...]
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
26/03/2026
Application supported by comprehensive clinical program, including two positive Phase 3 trials evaluating once-daily oral paltusotine in acromegaly SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals [...]
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for [...]
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
26/03/2026
Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results [...]
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
26/03/2026
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq. Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System ( [...]
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
26/03/2026
LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant [...]
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
26/03/2026
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phase 3, randomized, [...]

Pages